Administer: Behind the curve, earnings to recover - Evli
Administer's Q1 missed our estimates, with Silta and EmCe driving the sales shortfall and cost savings yet to fully offset lower volumes on profitability. FY26 guidance and management commentary signal an H2-led recovery.
ANNONS
Administer's Q1 missed our estimates, with Silta and EmCe driving the sales shortfall and cost savings yet to fully offset lower volumes on profitability. FY26 guidance and management commentary signal an H2-led recovery.